Jubilant Ingrevia Limited announced robust financial results for the fourth quarter and full fiscal year ending March 31, 2026. The company reported a 12% YoY increase in revenue and an 11% YoY rise in EBITDA for Q4 FY26. Key highlights include effective navigation of the Middle East crisis, successful dispatch from a new Agro CDMO facility, and strategic acquisition to bolster its Human Nutrition business. The company also announced a final dividend of ₹2.50 per share.
Jubilant Ingrevia Announces Strong Q4 and FY26 Performance
Jubilant Ingrevia Limited has reported a healthy financial performance for the fourth quarter (Q4) and the full fiscal year (FY26) ended March 31, 2026. The company achieved a 12% year-on-year (YoY) revenue growth and a significant 11% YoY increase in EBITDA for Q4 FY26, reflecting strong operational execution.
Key Business Highlights
A notable achievement during the quarter was the company’s successful management of the Middle East crisis, ensuring no force majeure and zero production loss. Other key developments include the successful dispatch from its newly constructed Agro CDMO facility and the strategic acquisition of Remidex to accelerate growth in its Human Nutrition segment. The Board of Directors has recommended a final dividend of ₹2.50 per share (250%), bringing the total FY26 dividend to ₹5 per share (500%).
Market Dynamics and Outlook
The chemical industry’s demand remains resilient despite Middle East disruptions, with volumes continuing to grow and pricing firming up due to higher crude-linked costs. Pharmaceuticals continue to drive growth with strong volumes. Agrochem has seen robust export visibility and successful price increases. The Nutrition and Personal Care markets experienced volume and price-led growth, particularly driven by Niacinamide.
Looking ahead, Jubilant Ingrevia is optimistic about its ‘Pinnacle journey’, anticipating strong EBITDA growth, an improved portfolio mix, and enhanced customer relationships. For FY27, the company expects growth to be led by Specialty Chemicals and Nutrition, along with a recovery in Acetyls. Sequential growth in revenue and EBITDA is anticipated starting from Q1 FY27.
Financial Performance Snapshot (Q4 FY26 vs. Q4 FY25)
- Total Revenue: Increased by 12% to ₹1,179 crore from ₹1,051 crore.
- Total EBITDA: Grew by 11% to ₹172 crore from ₹155 crore.
- PAT after Exceptional Items: Rose by 17% to ₹86 crore from ₹74 crore.
- Basic and Diluted EPS: Increased by 17% to ₹5.5 from ₹4.7.
Segment-wise Performance
Specialty Chemicals: Revenue grew by 6% to ₹516 crore, with EBITDA up by 8% to ₹139 crore. The segment’s contribution to overall revenue remained at 44%.
Nutrition & Health Solutions: Revenue saw a strong increase of 21% to ₹230 crore, while EBITDA grew by 9% to ₹32 crore. The segment’s share of overall revenue increased to 20%.
Chemical Intermediates: Revenue increased by 15% to ₹433 crore, but EBITDA decreased by 32% to ₹22 crore. This segment represented 37% of the overall revenue.
Debt Position
As of March 31, 2026, the Total Net Debt stood at ₹587 crore, reflecting a YoY change of -11%. Capex outflow for the quarter was ₹69 crore, primarily for commissioning of the CDMO plant at Bharuch and ground breaking for a new MPP at Gajraula. Net debt increased marginally due to higher working capital requirements, while working capital to revenue reduced to 16%.
Source: BSE
